Receive the latest updates from Matrix Medical in real time to understand product information.

Recently, the Hangzhou Science and Technology Bureau announced the list of "New Eagles" enterprises to be recognized in Hangzhou in 2024. With outstanding innovation achievements and development potential in the field of vascular intervention, Matrix Medical has been successfully selected as one of the first batch of "New Eagles" recognized enterprises, demonstrating its hardcore strength with authoritative qualification certification and becoming a key future industrial innovation force cultivated in Hangzhou.

The first batch of "New Eagle" enterprises awarded this time is not only an authoritative recognition of the innovation strength of Matrix Medical by the government, but also an important driving force for the development of the enterprise. In the future, Matrix will accurately invest policy rewards into the technological iteration and product upgrading in the field of vascular intervention, continuously deepen the "material innovation+technology transformation" dual wheel drive strategy, and accelerate the research and development process of the new generation of vascular intervention products.

From its debut at the Double Exhibition to its qualification coronation, Matrix Medical is steadily taking off on the high-end medical device innovation track with the posture of a "new eagle". We will continue to rely on policy empowerment and technological accumulation to bring more innovative solutions to the field of vascular intervention therapy, and move towards a higher quality development stage.

Award Introduction

 The "New Eagle" enterprise is a core measure taken by Hangzhou to strengthen the cultivation of technology enterprises at the source. It is a heavyweight qualification certification launched to cultivate innovative growth enterprises, focusing on high-quality enterprises with strong innovation capabilities, breakthroughs in segmented fields, and significant development potential.

Its recognition criteria not only focus on the fundamentals of enterprise operation, but also emphasize innovation hard indicators - meeting strict requirements in dimensions such as intellectual property reserves, technology research and development investment, and achievement transformation ability, which are important benchmarks for measuring the innovation vitality and growth value of enterprises. The reward funds provided by this policy will be directly used to support the core technology research and industrialization of enterprises, reflecting the government's precise support for high-quality innovative enterprises.

 treatment.

On September 26-28, 2025, the 9th Chinese Medical Association Neurointerventional Annual Conference and the 12th Chinese Neurointerventional Conference were grandly held in Changzhou. Top neurointerventional experts from all over the country gathered together to explore the forefront of the discipline and innovative development. As a representative enterprise in the field of domestic neural intervention, Xinwei Medical showcased its full range of solutions and presented a high-quality event integrating academic exchange and clinical practice with "new products and new technologies" as the core.